Source: globenewswire.com
Columbia based, Osiris Therapeutics (NASDAQ: OSIR), is engaged in the research, development, and manufacturing of regenerative medicine products intended to improve the health and lives of patients and lower overall healthcare costs. The Company achieved commercial success with products in orthopedics, sports medicine and wound care such as the Grafix product line, Stravix, BIO4®, and Cartiform. Recently, OSIR announced the appointment of Samson Tom to serve as President and Chief Executive Officer effective November 26, 2018. Samson has held several leadership positions since starting with the Company spanning multiple functional areas including Quality, Operations, Clinical Development, and Product Development. Prior to his role at OSIR, Samson served as Group Director, Biosurgery Research & Development at Ethicon, Inc.
